Jefferies Healthcare Conference. June 1, 2015
|
|
- Mavis Reynolds
- 5 years ago
- Views:
Transcription
1 Jefferies Healthcare Conference June 1, 2015
2 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However you should not place undue reliance on any such forward looking statements as these are subject to risks and uncertainties. Please refer to our press releases and our SEC filings for more information regarding the use of forward looking statements. 2 Confidential-Unilife
3 Business Overview Design, develop, manufacture and supply injectable drug delivery systems Long-term strategic partnerships with pharmaceutical and biotech companies A broad, highly differentiated portfolio for injectable biologics, drugs and vaccines Cash receipts from multiple sources, including device sales, upfront fees, milestone payments Several cornerstone supply agreements in place Anticipated recurring revenue over avg years with attractive operating margins at scale Business development efforts are active 3
4 Select Financial Information R&D investment accounts for more than half of total operating expense 60% 55% 54% 50% 45% 40% 41% R&D SG&A 35% 30% FY 2012 FY 2013 FY months to March 31, 2015 Revenue Cash Receipts from Customers Ending cash, and cash equivalents at March 31, 2015 (1) Quarter ended March 31, 2015 $2.9 $8.9 $ (1) Includes $2.1 M of restricted cash
5 Converging Market Trends Accelerating demand for safe, simple and convenient injectable drug delivery systems Complex Biologics Improving Therapy Compliance Reducing Healthcare Costs Enhancing Patient Lifestyles Patient Self- Injection Maximizing Drug Brand Differentiation 5
6 $m Large, Fast Growing Market for Injectable Drug Delivery Systems Projected market growth from $4B in 2015 to $15B by $18,000 $16,000 $14,000 $12,000 Wearable injectors^ $10,000 $8,000 $6,000 $4,000 Prefilled syringes* $2,000 $- Auto-injectors Reconstitution Ocular delivery Novel delivery ) ^ Roots Resarch. Wearable Bolus Injectors * VisionGain Medical Device Leader Series and Company estimates.
7 Our Business Strategy Commercial Pipeline Business development discussions are active Multiple potential drug candidates / customers Active Programs Device customization and other activities to prepare for commercial launch Signed customer agreements Upfront or milestone based cash receipts Programs may span 1 3 years or more prior to launch Commercial Supply Agreements Supply agreements signed prior to commercial launch yr. duration common Potential for multiple supply agreements per customer for various drugs, indications and / or devices 7
8 A Selection of Device Categories Customizable, Modular Product Platforms for Injectable Biologics, Drugs and Vaccines Prefilled Syringes Reconstitution Systems Auto-Injectors Wearable Injectors Ocular & Novel Delivery Systems 8
9 A Selection of Devices From Various Platforms Prefilled Syringes For prefilled drugs, vaccines and biologics Reconstitution Systems For liquid-liquid or liquid dry drug combinations Auto-Injectors Handheld self-injection therapies 9 Wearable Injectors For wearable self-injection therapies Ocular & Novel Delivery Systems For accurate, precise delivery to the eye and other organs
10 Integration of Drugs, Devices and Data for Therapy Adherence Aligned with customer programs and new commercial opportunities Integration of digital connectivity into select Unilife device platforms such as Smart reusable auto-injectors Integrated Data Hubs HIPAA authorized stakeholders such as: Patients Payers Prescribers Pharmaceutical Wearable injectors Custom options include Bluetooth LE, 4G and WIFI Adding healthcare value and patient outcomes Enhanced patient care Improved rates of therapy adherence Reduced healthcare costs 10
11 A Typical Strategic Customer Relationship Elements of a Strategic Relationship Commercial Benefits to Unilife Large portfolio of injectable drugs Customer has a multitude of biologics, drugs or vaccines in development and / or approved Multiple shots on goal Minimizes risk for launch Subsequent launches can increase revenue and rate of revenue growth Access to one or more Unilife device categories Customer desires platform for efficient customization of devices to specific needs of each drug Minimal sales and marketing Model expected to support attractive operating margins over time Long-term continuity of supply Customer requires assurance of device supply during development and commercial lifecycle Predictable, recurring revenues Supply agreements can span 10 to 15 years or more Minimum annual revenue anticipated during supply term Potential Exclusivity Customer seeks to maximize differentiation from competitors to build user preference and maximize market share Pre- Commercial Revenue Fees for exclusive access in disease area or indication Fees to customize device to specific brand requirements 11
12 A Selection of Long-Term Customer Agreements Customer Device Key Terms^ Sanofi AstraZeneca / MedImmune Sanofi Hikma Novartis Global biopharma company Unifill Finesse Wearable Injectors Wearable Injectors Unifill, Unifill Nexus, Unifill Allure Novel device for targeted organ delivery Unifill Finesse and LISA reusable auto-injector Global commercial supply for Lovenox. 10-Years. $50MM aggregate payments received. Min. 150MM units / year after ramp period. Global development and supply agreement. Several target biologics in MedImmune portfolio. Terms not disclosed. Unilife sole provider for all applicable large dose volume drugs. Global commercial supply biologics anticipated. 15-Years min. Global commercial supply. 20 generic injectables. 15-Years. $40MM in upfront and milestone payments. Min. 175MM units after ramp. Clinical development and supply. Terms not disclosed. Strategic agreement. $5MM for exclusive right to form and enter into mutually-agreeable development and supply agreement. Biodel EZMix Genesis Global supply for proprietary Glucagon product. 15-Years. Confidential Depot-ject Global commercial supply for approved ocular drug. 10-Years. Confidential Ocu-ject Confidential. Terms not disclosed. 12 ^ Refer to relevant press releases / SEC filings for additional information
13 Preparing for Commercial Rollout to Support Customer Ramp Programs Production Facilities 160,000 sq. ft. FDA-registered manufacturing facility in York, PA 11 clean rooms over 22,000 sq. ft. supporting existing programs Installation of extra 24,000 sq. ft of cleanroom space underway Strategic partnership with Flextronics provides access to Established production sites across four continents Efficient capital investment strategy to reduce cash flow needs during scale up Manufacturing Lines Unifill prefilled syringe platform Two lines in place Two lines scheduled CY st one million units expected to be shipped by the end of CY2015 Acceleration through Wearable injector platform Existing capacity up to 1MM units Initiate procurement of highspeed line during CY2015 Scale-up in other platforms according to customer ramp schedules Supplier Relationships Relationships with a series of established material suppliers for supply of components Primary and back-up suppliers in place for Unifill, wearable injectors and other platforms Open architecture model allows Unilife and customers to select preferred component materials Ability to leverage buying power of Flextronics and customers 13
14 Upcoming Milestones Existing Agreements Continued scale-up to commercial launch Commencement of new programs with additional molecules Anticipated human clinical studies with some target molecules Additional Agreements Multiple supply agreements with new and existing customers Other Commercial and Operational Highlights Development of additional Unilife products / device categories Financial Highlights Cash receipts from sales, customization programs and milestone-based fees Potential for significant upfront fees from customers seeking exclusivity access 14
CHARTING THE DEVELOPMENT OF A TRUE DIFFERENTIATED PORTFOLIO OF PARENTERAL DELIVERY SYSTEMS
CHARTING THE DEVELOPMENT OF A TRUE DIFFERENTIATED PORTFOLIO OF PARENTERAL DELIVERY SYSTEMS In this article, Alan Shortall, Chief Executive Officer, Unilife Corporation, describes how the company has developed
More informationDIFFERENTIATION WITHOUT DISRUPTION
DIFFERENTIATION WITHOUT DISRUPTION In this article, Alan Shortall, Chief Executive Officer, Unilife Corporation, describes a new paradigm now driving the pharmaceutical market for advanced drug delivery
More informationPre-filled, Pre-assembled, Ready-to-Inject.
Pre-filled, Pre-assembled, Ready-to-Inject. Peel, Stick, Click. Wearable Injectors T: +1 717 384 3400 E: info@unilife.com W: www.unilife.com These products have not yet been evaluated by the FDA SELECTING
More informationCRITERIA FOR SELECTING A WEARABLE INJECTOR TECHNOLOGY AND PARTNER
CRITERIA FOR SELECTING A WEARABLE INJECTOR TECHNOLOGY AND PARTNER In this article, Alan Shortall, Chief Executive Officer, Unilife, provides a detailed account of the significant opportunities that wearable
More informationSafe Harbor Statement
Safe Harbor Statement Sharps Compliance, Inc. Noble Financial Sixth Annual Equity Conference June 8, 2010 Safe Harbor Statement These slides contain (and the accompanying oral discussion will contain)
More informationJefferies 2016 Healthcare Conference. June 7, 2016
Jefferies 2016 Healthcare Conference June 7, 2016 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management
More informationPUTTING PATIENTS FIRST: INNOVATING DRUG CONTAINMENT AND DELIVERY
PUTTING PATIENTS FIRST: INNOVATING DRUG CONTAINMENT AND DELIVERY Innovations in self-administered drug delivery systems are supporting care for a variety of medical conditions transitioning out of hospitals
More information3.8.3 Plastic Pre-Filled Syringes: Drivers and Restraints
3.8.3 Plastic Pre-Filled Syringes: Drivers and Restraints 215-225 Figure 3.18 identifies the major drivers and restraints that will impact demand for plastic pre-filled syringes in the period 215-225.
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationAdams Conference Call to Discuss Acquisition of Delsym 12-Hour Cough Suppressant Liquids From UCB May 25, 2006
Adams Conference Call to Discuss Acquisition of Delsym 12-Hour Cough Suppressant Liquids From UCB May 25, 2006 Safe Harbor This presentation contains certain forward-looking statements. These statements
More informationDrug Delivery Forum 2018
Drug Delivery Forum 2018 Berlin, March 13, 2018 Portal Instruments 2018 1 Our Mission is to improve the experience for patients on life-changing therapies Portal Instruments 2018 2 1 in 2 American Adults
More informationLEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS
LEVERAGING OUR BIOLOGICS EXPERTISE IN BIOSIMILARS SCOTT FORAKER VICE PRESIDENT AND GENERAL MANAGER, BIOSIMILARS SAFE HARBOR STATEMENT This presentation contains forward-looking statements that are based
More informationPhylogica. Harnessing Biodiversity for Peptide Therapies. Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development
Phylogica Harnessing Biodiversity for Peptide Therapies Life Sciences Showcase, 23 August 2011 Nick Woolf: CFO & VP Corporate Development Introduction Biotech company offering leading peptide drug discovery
More informationFirst Quarter Trusted by the Life Sciences Industry
First Quarter 2018 Trusted by the Life Sciences Industry 1 Safe Harbor Forward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties. Such
More informationDIFFERENTIATION WITHOUT DISRUPTION
DIFFERENTIATION WITHOUT DISRUPTION Significant commercial opportunities exist for pharmaceutical companies willing to raise the industry benchmark and supply their drugs and vaccines in innovative devices
More informationSupplemental Financial Schedules May 19, 2015
Supplemental Financial Schedules May 19, 2015 The presentations and related schedules contain financial measures that are not calculated in accordance with generally accepted accounting principles (GAAP).
More informationAbout the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive
About the Healthcare Strategic Analysis Team Geographic specific reports: Global issue reports: 1. About This Report Chapter structure Executive summary Licensing trends overview Evolving trends in the
More informationEXANE Conference. Jérôme Contamine, Executive Vice President, Chief Financial Officer. Paris June 13, 2017
EXANE Conference Jérôme Contamine, Executive Vice President, Chief Financial Officer Paris June 13, 2017 Forward Looking Statements This presentation contains forward-looking statements as defined in the
More informationJanuary 2019 Investor Presentation NASDAQ: ATRS
January 2019 Investor Presentation NASDAQ: ATRS Safe Harbor Statement This presentation contains forward looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation
More informationCorporate Presentation January 2019
Corporate Presentation January 2019 Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on our management s current expectations
More informationJefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q
Jefferies 2014 Global Healthcare Conference June 3, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements
More informationDEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE
CATALYSTS DRIVING SUCCESSFUL DECISIONS IN LIFE SCIENCES DEMONSTRATING YOUR MEDICINE S VALUE TO ALL STAKEHOLDERS TRUSTED COMMERCIALIZATION AND MARKET ACCESS EXPERTISE WHEN COMMERCIALIZING A MEDICINE, IT
More informationDeutsche Bank Healthcare Conference
Deutsche Bank Healthcare Conference Jérôme Contamine, Executive Vice President, Chief Financial Officer Boston May 4, 2017 Forward Looking Statements This presentation contains forward-looking statements
More informationBid Energy 2018 AGM MD s Report Guy Maine, Managing Director
For personal use only Bid Energy 2018 AGM MD s Report Guy Maine, Managing Director 2For personal use only On an upward trajectory 2018 marks a turning point for Bid Energy We ve delivered an improved commercial
More information34 th Annual J.P. Morgan Healthcare Conference
34 th Annual J.P. Morgan Healthcare Conference Vincent A. Forlenza Chairman, Chief Executive Officer and President January 13, 2016 Forward-Looking Statements These materials include forward-looking statements
More informationCapabilities Overview Presentation. Presenter
Capabilities Overview Presentation Presenter About Baxter Global, diversified healthcare company 80 years of parenteral expertise driven by a well recognized global brand $12.6 billion global market leader
More informationEnvironmental Services Conference
Sharps Compliance Corp. NASDAQ: SMED Credit Suisse Industrial and Environmental Services Conference May 24, 2011 Diana P. Diaz Vice President and Chief Financial Officer 1 Safe Harbor Statement These slides
More informationInvestor Presentation June 2006
Investor Presentation June 2006 Safe Harbor This presentation contains certain forward-looking statements. These statements are based on the current estimates and assumptions of the management of Adams
More informationJ.P. Morgan Healthcare Conference January 10, 2018
J.P. Morgan Healthcare Conference January 10, 2018 Safe Harbor This presentation is intended to be disclosure through methods reasonably designed to provide broad, non-exclusionary distribution to the
More informationCOMPANY PRESENTATION Marshall Chesrown Chairman & CEO
COMPANY PRESENTATION Marshall Chesrown Chairman & CEO FORWARD-LOOKING STATEMENTS & PROJECTIONS This presentation includes financial forecasts, projections, and other forward-looking statements regarding
More informationto acquire Investor And Analyst Call Presentation January 4, 2008
to acquire Investor And Analyst Call Presentation January 4, 2008 Safe Harbor Statement The following information contains, or may be deemed to contain, forward looking statements (as defined in the U.S.
More informationHospira 2007 Investor Day. APAC Region. Tim Oldham, Ph.D. President, Asia-Pacific. Advancing Wellness. through the right people and the right products
Hospira 2007 Investor Day APAC Region Tim Oldham, Ph.D. President, Asia-Pacific Advancing Wellness through the right people and the right products The APAC Region Asia in Brief: 58% of the world s population
More informationAstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review
AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review BioPortfolio has been marketing business and market research reports
More informationQuarter End Results. Period Ended September 30, 2018
Quarter End Results Period Ended September 30, 2018 Forward Looking Statement This presentation contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions
More informationERI INVESTOR PRESENTATION
ERI INVESTOR PRESENTATION (NASDAQ: ERII) Jefferies Energy Conference 2016 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the Safe Harbor provisions of the Private
More informationImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update
August 2, 2013 ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2013 Financial Results and Provides Fiscal Year 2014 Financial Guidance and Corporate Update Kadcyla sales off to strong start. Decision
More informationModerna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 2016 Strategic Priorities
Moderna Therapeutics Announces Transition to a Clinical Stage Company, Provides Business Update and Outlines 26 Strategic Priorities First Phase I study underway in Europe for mrna 44; IND for second program,
More informationForesee Pharmaceuticals, Inc.
Foresee Pharmaceuticals, Inc. Rapid Development and Commercialization of a Proprietary Sustained-release Depot Formulation of Leuprolide for the Treatment of Advanced Prostate Cancer PNWBIO Meeting 10
More informationSanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care
Sanofi to Acquire Bioverativ A Strategically and Financially Compelling Acquisition in Specialty Care January 22, 2018 Forward Looking Statements This presentation contains forward-looking statements.
More informationOracle Buys ClearTrial Adds Leading Cloud-based Clinical Trial Operations and Analytics Applications to the Oracle Health Sciences Suite
Oracle Buys ClearTrial Adds Leading Cloud-based Clinical Trial Operations and Analytics Applications to the Oracle Health Sciences Suite April 12, 2012 Oracle is currently reviewing
More informationTrump Biotech Special: A $7 Stock with Yuge Potential. Trump Biotech Special: A $7 Stock with Yuge Potential
Trump Biotech Special: A $7 Stock with Yuge Potential Xenon Pharmaceuticals: Vastly Undervalued With Yuge Potential It seems appropriate after all but secured the Republican nomination to highlight a small
More informationTrinity ConTRact: Cornerstone Projects in Contracting Strategy
Trinity ConTRact: Cornerstone Projects in Contracting Strategy With mounting external pressures limiting access and tightening reimbursement, effective contracting is critical to the commercial success
More informationBank of America Merrill Lynch Healthcare Conference. September 13, 2013
Bank of America Merrill Lynch Healthcare Conference September 13, 2013 Safe Harbor Statement This presentation contains forward-looking statements that are based on management s current expectations and
More informationInvestor Presentation May Stephen Wiehe, CEO Rudy Howard, CFO
Investor Presentation May 2015 Stephen Wiehe, CEO Rudy Howard, CFO FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements. Forward-looking statements include information concerning
More informationA Biotech Blockbuster in the $60 Billion Pet Industry. A Biotech Blockbuster in the $60 Billion Pet Industry
A Biotech Blockbuster in the $60 Billion Pet Industry Artana Therapeutics: Off the Radar and Undervalued Our next profile is a unique biopharma that is literally for the dogs, and that is a good thing
More informationAnika Therapeutics, Inc.
Anika Therapeutics, Inc. Jefferies Global Healthcare Conference June 4, 2015 Safe Harbor Statement The statements made in this presentation that are not statements of historical fact are forward looking
More informationSafe Harbor Statement
Safe Harbor Statement Sharps Compliance Corp. NASDAQ: SMED William Blair Emerging Growth Stock Conference October 5, 2010 David P. Tusa Chief Executive Officer and President Safe Harbor Statement These
More informationJanuary (San Francisco, CA) January 8, 2018
January 2017 J.P. Morgan 36 th Annual Management Healthcare Presentation Conference (San Francisco, CA) January 8, 2018 DISCLAIMER Certain information contained in this presentation relates to or is based
More informationCryoport, Inc. Calendar Year 2017 Third Quarter Earnings Call NASDAQ: CYRX
Cryoport, Inc. Calendar Year 2017 Third Quarter Earnings Call 1 Safe Harbor Forward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties.
More informationRaymond James 34th Annual Institutional Investors Conference
Raymond James 34th Annual Institutional Investors Conference Thomas Werner, CFO March 5, 2013 Safe Harbor This material contains forward-looking statements within the meaning of the U.S. federal securities
More informationEagle Pharmaceuticals NASDAQ: EGRX
Eagle Pharmaceuticals NASDAQ: EGRX Scott Tarriff, CEO David Riggs, CFO June 2015 Forward Looking Statements This presentation contains certain forward-looking information about Eagle Pharmaceuticals that
More informationNYSE American: PFNX Corporate Presentation
NYSE American: PFNX Corporate Presentation Pfenex Safe Harbor Statement This presentation, including the accompanying oral presentation (the Presentation ), includes forward-looking statements within the
More informations c i e n c e q u a l i t y i n n o v a t i o n
s c i e n c e q u a l i t y i n n o v a t i o n FORWARD LOOKING STATEMENTS This presentation may contain certain statements including, without limitation, the words may, plan, will, estimate, continue,
More informationAccelerating our strategy: GSK to acquire full ownership of Consumer Healthcare Business
Accelerating our strategy: GSK to acquire full ownership of Consumer Healthcare Business Buyout of Novartis stake Strategic review of Horlicks and other Consumer Healthcare Nutrition products Cautionary
More informationPfenex Inc. San Diego, CA NYSE MKT: PFNX. Updated July 2017
Pfenex Inc. San Diego, CA NYSE MKT: PFNX Updated July 2017 Safe Harbor Statement This presentation (the Presentation ) includes forward looking statements within the meaning of the Private Securities Litigation
More informationCapital Market Day June 12, 2012
Capital Market Day 2012 June 12, 2012 Product Segments IV Drugs John Ducker Member of the Management Board President Region North America Capital Market Day Fresenius Kabi, June 12, 2012 Agenda 1 2 3 4
More informationAkcea Therapeutics, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationAusbiotech Biotech Invest Summit
ASX code: LBT lbtinnovations.com Ausbiotech Biotech Invest Summit 3 December 2014 Lusia Guthrie, CEO Disclaimer This document contains certain forward-looking statements that involve risks and uncertainties.
More informationI. Company Information
Please fill out this form as completely as possible. Note: There is no fee to apply. Please send additional materials such as your pitch deck and executive summary to resi@lifesciencenation.com for us
More informationQuarter End Results. Period Ended June 30, 2018
Quarter End Results Period Ended June 30, 2018 Forward Looking Statement This presentation contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions
More informationINVITAE: Genetics from downstream to mainstream U B S G L O B A L H E A LT H C A R E C O N F E R E N C E
INVITAE: Genetics from downstream to mainstream U B S G L O B A L H E A LT H C A R E C O N F E R E N C E 2 0 1 7 Safe harbor statement This presentation contains forward-looking statements within the meaning
More informationSobi to acquire Synagis US rights from AstraZeneca - Creates a platform for global growth. Investor Presentation l 13 November 2018
Sobi to acquire Synagis US rights from AstraZeneca - Creates a platform for global growth Investor Presentation l 13 November 2018 Forward looking statements In order to utilise the Safe Harbor provisions
More informationThe generics environment today
The generics environment today Sergio Napolitano EGA Director Legal Affairs and Trade 2 October 2015, Warsaw C O M PA N I E S N AT I O N A L A S S O C I AT I O N S EGA Membership GE (Hungary) SPMA (Slovenia)
More informationSobi Update and Perspective Jefferies Healthcare Conference
Sobi Update and Perspective Jefferies Healthcare Conference Geoffrey McDonough CEO London 19 November 2014 Forward Looking Statements In order to utilize the Safe Harbor provisions of the United States
More informationCortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly
Cortendo and Antisense Therapeutics Announce Licensing Agreement for ATL1103 for Acromegaly May 14, 2015 Goteborg, Sweden and Trevose, Pa., USA and Victoria, Australia Cortendo AB (publ) [ticker: CORT
More informationQUALITY & SAFETY CHARACTERISTICS OF PREFILLABLE SYRINGE SYSTEMS: HAZARD CONCERNS & MITIGATION STRATEGIES
QUALITY & SAFETY CHARACTERISTICS OF PREFILLABLE SYRINGE SYSTEMS: HAZARD CONCERNS & MITIGATION STRATEGIES Advancement of regulatory science, innovation, safety and integrity of the global pharmaceutical
More informationFor personal use only
Simavita Australian investor briefing presentation For Immediate Release: June 24, 2015 Sydney, Australia Simavita Limited ( Simavita or the Company ) (TSX-V: SV; ASX: SVA), a global leader in the digital
More informationAkcea Therapeutics, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationTeva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference. Kåre Schultz President and CEO January 7, 2019
Teva Pharmaceutical Industries Ltd. J.P. Morgan Healthcare Conference Kåre Schultz President and CEO January 7, 2019 Cautionary Note Regarding Forward-Looking Statements 2 This presentation contains forward-looking
More informationA NEW VALUE PROPOSITION OF SMART DEVICES: ADVANCED MEDICATION ADHERENCE MONITORING IN CLINICAL TRIALS
A NEW VALUE PROPOSITION OF SMART DEVICES: ADVANCED MEDICATION ADHERENCE MONITORING IN CLINICAL TRIALS Andreas Schneider, PhD, Business Development Manager, Ypsomed AG, explores a new value proposition
More informationDriving Commercial Excellence in our US business
Driving Commercial Excellence in our US business Jefferies 2016 Healthcare Conference 4 Perry Sternberg Head of US Commercial June 9th, 2016 SAFE HARBOR Statement Under the Private Securities Litigation
More informationAVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update
AVEO Oncology Reports Third Quarter 2016 Financial Results and Provides Business Update CAMBRIDGE, Mass. November 4, 2016 AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter
More information31st Annual J.P. Morgan Healthcare Conference
Quest Diagnostics 31st Annual J.P. Morgan Healthcare Conference January 9, 2013 Safe Harbor Disclosure This presentation may contain forward looking statements. Readers are cautioned not to place undue
More informationI. Company Information
If your company won (1st-3rd place) an Innovation Challenge since RESI JPM 2018, or were a finalist at RESI NYC 2018, you do not qualify to participate in the Innovation Challenge at RESI JPM 2019. Please
More informationPfenex Inc. San Diego, CA NYSE MKT: PFNX
Pfenex Inc. San Diego, CA NYSE MKT: PFNX Safe Harbor Statement This presentation (the Presentation ) includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationFourth Quarter and Full Year Financial and Operational Results Conference Call March 21, 2018
Fourth Quarter and Full Year 2017 Financial and Operational Results Conference Call March 21, 2018 Copyright Akari Therapeutics, Plc - 2018 Disclaimers Certain statements in this presentation constitute
More informationpsivida Corp PSDV June 2016
psivida Corp PSDV June 2016 Safe Harbor Statement Safe Harbor Statement SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking,
More informationHospira 2007 Investor Day
0 Hospira 2007 Investor Day Hospira 2007 Investor Day Research and Development Edward A. Ogunro, Ph.D. Senior Vice President, Research & Development and Medical Affairs, and Chief Scientific Officer Advancing
More informationADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless.
ADVANCING SCIENTIFIC INNOVATION Together, the possibilities are endless. COMMUNICATE INNOVATE EXPLORE COLLABORATE PARTNERSHIPS THAT BENEFIT YOU, US, AND ALL OF MANKIND Since Eli Lilly and Company was founded
More informationARNAUD GUILLET, BIOCORP
RNUD GUILLET, BIOCORP rnaud Guillet is Business Development ssociate at Biocorp, in charge of finding partnerships and license opportunities for Biocorp s range of connected devices. Previously, Guillet
More informationReal solutions for real-world problems.
Digital Health Real solutions for real-world problems. Today, it costs around $2.6 billion and takes between 10 and 15 years to develop a new drug. 1 Despite the enormity of this investment, once the drug
More informationBOUNDARYLESS RETAIL: leveraging content, community and commerce. Investor Presentation Fourth Quarter 2010
BOUNDARYLESS RETAIL: leveraging content, community and commerce Investor Presentation Fourth Quarter 2010 SAFE HARBOR STATEMENT This presentation may contain forward-looking statements relating to the
More informationDeutsche Bank Health Care Conference
Deutsche Bank Health Care Conference May 8, 2018 NASDAQ: ANIK0 Safe Harbor Statement The statements made in, and during the course of, this presentation that are not statements of historical fact, including
More informationNew Health Data Economy: Strategic Partnerships with Life Sciences Company
New Health Data Economy: Strategic Partnerships with Life Sciences Company Pravin R Jadhav Sr. Director, Innovative Data Solutions Otsuka Data Sciences Otsuka Pharmaceutical Development and Commercialization
More informationSafe Harbor. J.P. Morgan 30th Annual Healthcare Conference January 10, 2012
J.P. Morgan 30th Annual Healthcare Conference January 10, 2012 Safe Harbor This material contains forward-looking statements within the meaning of the federal securities laws. intends these forward-looking
More informationRockwell Medical Investor Presentation MARCH 2019
Rockwell Medical Investor Presentation MARCH 2019 Forward Looking Language Certain statements in this presentation may constitute "forward-looking statements" within the meaning of the federal securities
More informationCompany Presentation 2018
Company Presentation 2018 1 2 Safe harbor statement This presentation contains forward-looking statements. These statements may relate to, but are not limited to, expectations of future results of operations
More informationNew Cardinal Health (Post-Spin)
New Cardinal Health (Post-Spin) George Barrett Vice Chairman and Chief Executive Officer Healthcare Supply Chain Services and Chief Executive Officer Cardinal Health, Inc. (post-spin) January 14, 2009
More informationSafe Harbor Statement
Safe Harbor Statement Sharps Compliance Corp. NASDAQ: SMED Barrington Consumer & Business Services Conference December 9, 2010 David P. Tusa Chief Executive Officer and President Diana P. Diaz Chief Financial
More informationENABLE INJECTIONS AND FLEX SET AMBITIOUS PLANS FOR LARGE VOLUME DRUG DELIVERY
ENABLE INJECTIONS AND FLEX SET AMBITIOUS PLANS FOR LARGE VOLUME DRUG DELIVERY The delivery of high volumes of biologics outside of the clinical setting remains a key challenge in the industry. Here, John
More informationMEETING THE INCREASING REQUIREMENTS FOR HUMAN FACTORS CONSIDERATIONS
MEETING THE INCREASING REQUIREMENTS FOR HUMAN FACTORS CONSIDERATIONS Human factors engineering (HFE) is now an essential requirement for all new drug delivery combination product approvals to ensure devices
More informationRTIX Investor Presentation
RTIX Investor Presentation Camille Farhat President and CEO Jonathon Singer CF&AO September 2018 Forward Looking Statements This communication contains forward-looking statements within the meaning of
More informationI. Company Information
Please fill out this form as completely as possible. Note: There is no fee to apply. Please send additional materials such as your pitch deck and executive summary to resi@lifesciencenation.com for us
More informationInvestor Presentation. January 12, 2017
Investor Presentation January 12, 2017 SAFE HARBOR STATEMENT This presentation contains certain forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking
More informationHospira 2007 Investor Day
1 Hospira 2007 Investor Day Hospira 2007 Investor Day Strategic Overview Christopher B. Begley Chairman and Chief Executive Officer Advancing Wellness through the right people and the right products Safe
More informationUPS Healthcare Supply Chain Vital Signs
UPS Study Executive September 2017 START 2017 UPS Survey 2017 United Parcel Service of America, Inc. 1 An industry growing more complex: managing competition, compliance and costs Pharmacies are grappling
More informationGuide to Valuation of Pharmaceutical Licensing Deals
Guide to Valuation of Pharmaceutical Licensing Deals Edited by Taskin Ahmed and Heather Cartwright SYNDICATED ANALYTICS PHARMADEALS Contents 1 Introduction... 7 1.1 Dealmaking in the Pharmaceutical Industry...
More informationCL King Best Ideas Conference
Leadership in Surface Modification and Drug Delivery Phil Ankeny, Senior Vice President and CFO CL King Best Ideas Conference The Omni Berkshire Place Hotel September 19, 2007 Safe Harbor Statement Some
More informationOmnicell, Inc. Investor Presentation. April, 2018
Omnicell, Inc. Investor Presentation April, 2018 1 Safe Harbor Statement This presentation contains certain forward-looking statements. These statements are based on the current estimates and assumptions
More information